Follow The Filings

ORKA Oruka Therapeutics Inc.

Health Care, filed as ORUKA THERAPEUTICS INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Sold by 2 managers in 2026 Q2

  • 3 Owners
  • Max 11.6%
  • $219M
  • 2 reduce

In 2026 Q2 Palo Alto Investors and Andreas Halvorsen trimmed Oruka Therapeutics.

Who owns this now

Largest portfolio weights among holders, up to 11.6% (David Witzke, Avidity Partners Management). Not free-float ownership.

  1. David Witzke 11.6%
  2. Palo Alto Investors Reduce 0.44%
  3. Andreas Halvorsen Reduce 0.41%

Who owns ORKA

Sorted by value, long equity only, as of 2026 Q2.

History
Andreas Halvorsen, Viking Global Investors 0.41% Reduce −43.6% 1,503,478 $143M History
David Witzke, Avidity Partners Management 11.6% Hold 760,424 $72M History
Palo Alto Investors 0.44%, was 0.45% Reduce −44.1% 33,546 $3.2M History

3 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by ORKA's executives, directors and 10% owners in the last 12 months, from their Form 4s

All ORKA insider trades
  • None no insider bought on the open market
  • $300M sold by 1 insider outside a trading plan
  • $36.6M sold by 6 insiders under 10b5-1 plans
  1. Paul T Quinlan General Counsel
    Planned sale
    $707K 9,000 shares at $78.53 23% of stake
    Traded Oct 20 Filed Oct 20
    ↗
  2. Joana Goncalves Chief Medical Officer
    Planned sale
    $524K 7,000 shares at $74.81 18% of stake
    Traded Oct 15 Filed Oct 15
    ↗
  3. Arjun Agarwal Senior Vice President, Finance
    Planned sale
    $806K 9,999 shares at $80.60 41% of stake
    Traded Oct 12 Filed Oct 13
    ↗
  4. Lawrence Otto Klein CEO
    Planned sale
    $2.1M 25,000 shares at $83.62 2.6% of stake
    Traded Oct 1 Filed Oct 2
    ↗
  5. Arjun Agarwal Senior Vice President, Finance
    Planned sale
    $51K 533 shares at $95.75 3.6% of stake
    Traded Sep 21 Filed Sep 21
    ↗
  6. Paul T Quinlan General Counsel
    Planned sale
    $936K 10,000 shares at $93.64 25% of stake
    Traded Sep 21 Filed Sep 21
    ↗
  7. Joana Goncalves Chief Medical Officer
    Planned sale
    $644K 7,000 shares at $91.93 18% of stake
    Traded Sep 15 Filed Sep 15
    ↗
  8. Arjun Agarwal Senior Vice President, Finance
    Planned sale
    $872K 9,459 shares at $92.23 38% of stake
    Traded Sep 11 Filed Sep 15
    ↗
  9. Laura Lee Sandler COO
    Planned sale
    $459K 5,000 shares at $91.82 2.1% of stake
    Traded Sep 1 Filed Sep 1
    ↗
  10. Lawrence Otto Klein CEO
    Planned sale
    $6.9M 75,000 shares at $91.83 7.5% of stake
    Traded Sep 1 Filed Sep 1
    ↗
  11. Joana Goncalves Chief Medical Officer
    Planned sale
    $783K 7,000 shares at $111.84 18% of stake
    Traded Aug 17 Filed Aug 17
    ↗
  12. Paul T Quinlan General Counsel
    Planned sale
    $5.6M 52,000 shares at $108.49 63% of stake
    Traded Aug 14 Filed Aug 14
    ↗
  13. Arjun Agarwal Senior Vice President, Finance
    Planned sale
    $1.1M 10,000 shares at $106.66 40% of stake
    Traded Aug 13 Filed Aug 14
    ↗
  14. Joana Goncalves Chief Medical Officer
    Planned sale
    $604K 7,000 shares at $86.28 18% of stake
    Traded Jul 15 Filed Jul 15
    ↗
  15. Arjun Agarwal Senior Vice President, Finance
    Planned sale
    $846K 9,999 shares at $84.63 40% of stake
    Traded Jul 13 Filed Jul 13
    ↗

Also filed in the last 12 months, not counted as buying or selling: 48 option exercises, 15 sales to cover taxes, 6 stock grants, 1 conversion, and 1 other transaction.

SEC filings

Recent issuer filings from EDGAR, 10 shown.

Filed Form Detail Links
424B5 PROSPECTUS Filing Doc
8-K 5.02,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q QUARTERLY REPORT Filing Doc
SCHEDULE 13D/A — Filing Doc
8-K 5.07 Filing Doc

Source: SEC EDGAR submissions, updated 2 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $0.00 — —
Net income -$5.34M -$83.72M -$105.43M

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $37.59M $0.001M $343.86M
Total non-current assets * $0.269M $0M $144.76M
Total assets $37.86M $0.001M $488.62M
Total current liabilities $0.637M $13.04M $15.37M
Total non-current liabilities * $0.204M $0.755M $1.31M
Total equity $37.02M $0.001M $471.93M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$5.01M -$57.84M -$88.21M
Cash from investing $0M -$330.13M -$96.74M
Cash from financing $0M $449.54M $170.32M
Net change in cash * -$5.01M $61.58M -$14.64M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.